15596 Federal Register / Vol. 89, No. 43 / Monday, March 4, 2024 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Benjamin Hurley at 240–276–5489 or 

benjamin.hurley@nih.gov. Licensing 

information may be obtained by 

communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852: tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Vaccinia Virus Strain WR With 

Deletion of Growth Factor Genes 

(‘‘vSC20’’) 

Description of Technology: 

This technology relates to mutant 

vaccinia virus expression vectors. 

Researchers at NIAID have developed a 

recombinant vaccinia virus in which the 

growth factor genes were deleted from 

both ends of the genome. The 

recombinant vaccinia virus is attenuated 

and can replicate efficiently in rapidly 

dividing cells such as tumors. 

The mutation in the recombinant 

virus was confirmed through various 

tests, including Southern blot analysis 

and growth factor assays. The mutant 

expression vectors show diminished 

virus replication in non-dividing cells 

and attenuation in animal models 

compared to other vaccinia virus 

expression vectors. They may have use 

as vaccines, cancer therapies as well as 

for gene delivery. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• Recombinant vaccinia virus with 

deletion of growth factor genes can be 

used for cancer therapeutics and 

diagnostics. 

Competitive Advantages: 

• The recombinant vaccinia virus is 

attenuated and can replicate efficiently 

in rapidly dividing cells, such as 

tumors. 

• Applications include use in tumordirected gene therapy, given the 

enhanced safety profile, tumor 

selectivity, and the oncolytic effects 

after systemic delivery. 

Development Stage: 

• Pre-Clinical. 

Inventors: Bernard Moss, M.D., Ph.D. 

and Sekhar Chakrabarti, Ph.D., both of 

NIAID. 

Publications: Buller, R M et al. 

‘‘Deletion of the vaccinia virus growth 

factor gene reduces virus virulence.’’ 

Journal of virology vol. 62,3 (1988): 866– 

74. doi:10.1128/JVI.62.3.866–874.1988; 

McCart, J A et al. ‘‘Systemic cancer 

therapy with a tumor-selective vaccinia 

virus mutant lacking thymidine kinase 

and vaccinia growth factor genes.’’ 

Cancer research vol. 61,24 (2001): 8751– 

7. 

Intellectual Property: HHS Reference 

No. E–028–2021. U.S. Patent 

8506947B2, issued on August 13, 2013. 

Licensing Contact: To license this 

technology, please contact Benjamin 

Hurley at 240–276–5489 or benjamin.

hurley@nih.gov and reference E–028– 

2021. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. For 

collaboration opportunities, please 

contact Benjamin Hurley at 240–276– 

5489 or benjamin.hurley@nih.gov. 

Dated: February 14, 2024. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2024–04424 Filed 3–1–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Peter Tung at 240–669–5483 or peter.

tung@nih.gov. Licensing information 

may be obtained by communicating 

with the Technology Transfer and 

Intellectual Property Office, National 

Institute of Allergy and Infectious 

Diseases, 5601 Fishers Lane, Rockville, 

MD 20852: tel. 301–496–2644. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of 

unpublished information related to the 

invention. 

Licensing information and copies of 

the patent applications listed below may 

be obtained by communicating with the 

Technology Transfer and Intellectual 

Property Office, National Institute of 

Allergy and Infectious Diseases, 5601 

Fishers Lane, Rockville, MD 20852 by 

contacting Peter Tung at 240–669–5483 

or peter.tung@nih.gov. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of 

unpublished patent applications related 

to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Enhanced Single-Component AMA1– 

RON2 Vaccine Candidates: A 

Breakthrough in Malaria Immunization 

Description of Technology 

This technology focuses on the 

creation of single-component AMA1– 

RON2 (Apical membrane antigen 1- 

rhoptry neck protein 2) vaccine 

candidates. These candidates are based 

on a novel composition of matter 

designed to elicit a more effective 

immune response against the malaria 

parasite Plasmodium falciparum. The 

standout aspect of this technology is the 

Structure-Based Design 1 (SBD1) 

immunogen, engineered through a 

structure-based design that significantly 

enhances its ability to produce potent, 

strain-transcending neutralizing 

antibodies. This approach not only 

surpasses the efficacy of traditional 

AMA1–RON2 complexes and other 

insertion fusion designs but also boasts 

higher thermal stability, indicating 

better preservation and longevity of the 

vaccine. The technology’s increased 

stability and efficiency in production 

present an opportunity to lower vaccine 


khammond on DSKJM1Z7X2PROD with NOTICES